Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease
- PMID: 35294663
- DOI: 10.1007/s00702-022-02480-x
Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease
Abstract
Prof. Dr. Peter Riederer, the former Head of the Neurochemistry Department of the Psychiatry and Psychotherapy Clinic at the University of Würzburg (Germany), has been one of the pioneers of research into oxidative stress in Parkinson's and Alzheimer's disease (AD). This review will outline how his scientific contribution to the field has opened a new direction for AD treatment beyond "plaques and tangles". In the 1990s, Prof. Riederer was one of the first scientists who proposed oxidative stress and neuroinflammation as one of the major contributors to Alzheimer's disease, despite the overwhelming support for the "amyloid-only" hypothesis at the time, which postulated that the sole and only cause of AD is β-amyloid. His group also highlighted the role of advanced glycation end products, sugar and dicarbonyl-derived protein modifications, which crosslink proteins into insoluble aggregates and potent pro-inflammatory activators of microglia. For the treatment of chronic neuroinflammation, he and his group suggested that the most appropriate drug class would be cytokine-suppressive anti-inflammatory drugs (CSAIDs) which have a broader anti-inflammatory action range than conventional non-steroidal anti-inflammatory drugs. One of the most potent CSAIDs is curcumin, but it suffers from a variety of pharmacokinetic disadvantages including low bioavailability, which might have tainted many human clinical trials. Although a variety of oral formulations with increased bioavailability have been developed, curcumin's absorption after oral delivery is too low to reach therapeutic concentrations in the micromolar range in the systemic circulation and the brain. This review will conclude with evidence that rectally applied suppositories might be the best alternatives to oral medications, as this route will be able to evade first-pass metabolism in the liver and achieve high concentrations of curcumin in plasma and tissues, including the brain.
Keywords: Brain; Curcumin; Dementia; Glycation; Inflammation; Suppositories.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Similar articles
-
Neuroprotective and anti-inflammatory effects of curcumin in Alzheimer's disease: Targeting neuroinflammation strategies.Phytother Res. 2024 Jun;38(6):3169-3189. doi: 10.1002/ptr.8200. Epub 2024 Apr 14. Phytother Res. 2024. PMID: 38616356 Review.
-
Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.CNS Drugs. 2019 May;33(5):457-480. doi: 10.1007/s40263-019-00619-1. CNS Drugs. 2019. PMID: 30900203 Review.
-
Curcumin-loaded polymeric nanomaterials as a novel therapeutic strategy for Alzheimer's disease: A comprehensive review.Ageing Res Rev. 2024 Aug;99:102393. doi: 10.1016/j.arr.2024.102393. Epub 2024 Jun 24. Ageing Res Rev. 2024. PMID: 38925479 Review.
-
Neuroinflammation in Alzheimer's Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals.Adv Protein Chem Struct Biol. 2017;108:33-57. doi: 10.1016/bs.apcsb.2017.02.001. Epub 2017 Mar 22. Adv Protein Chem Struct Biol. 2017. PMID: 28427563 Review.
-
High bioavailability curcumin: an anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation.Arch Toxicol. 2017 Apr;91(4):1623-1634. doi: 10.1007/s00204-017-1939-4. Epub 2017 Feb 15. Arch Toxicol. 2017. PMID: 28204864 Review.
Cited by
-
Dual Mechanism of Action of Curcumin in Experimental Models of Multiple Sclerosis.Int J Mol Sci. 2022 Aug 4;23(15):8658. doi: 10.3390/ijms23158658. Int J Mol Sci. 2022. PMID: 35955792 Free PMC article.
-
The effects of a highly bioavailable curcumin PhytosomeTM preparation on the retinal architecture and glial reactivity in the GFAP-IL6 mice.Front Ophthalmol (Lausanne). 2023 Oct 6;3:1205542. doi: 10.3389/fopht.2023.1205542. eCollection 2023. Front Ophthalmol (Lausanne). 2023. PMID: 38983084 Free PMC article.
-
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses.Aging Dis. 2024 Feb 1;15(1):43-73. doi: 10.14336/AD.2023.0608. Aging Dis. 2024. PMID: 37450931 Free PMC article. Review.
-
Balancing Microglial Density and Activation in Central Nervous System Development and Disease.Curr Issues Mol Biol. 2025 May 9;47(5):344. doi: 10.3390/cimb47050344. Curr Issues Mol Biol. 2025. PMID: 40699743 Free PMC article. Review.
-
Oral administration of an integrative supplement (CogniCaps®) improves cognitive scores in aging dogs with canine cognitive dysfunction for at least two months: An open-label investigation in 10 dogs.Open Vet J. 2023 Feb;13(2):188-192. doi: 10.5455/OVJ.2023.v13.i2.6. Epub 2023 Feb 11. Open Vet J. 2023. PMID: 37073246 Free PMC article.
References
-
- Alsema AM, Jiang Q, Kracht L, Gerrits E, Dubbelaar ML, Miedema A, Brouwer N, Hol EM, Middeldorp J, van Dijk R, Woodbury M, Wachter A, Xi S, Moller T, Biber KP, Kooistra SM, Boddeke E, Eggen BJL (2020) Profiling Microglia From Alzheimer’s disease donors and non-demented elderly in acute human postmortem cortical tissue. Front Mol Neurosci 13:134. https://doi.org/10.3389/fnmol.2020.00134 - DOI - PubMed - PMC
-
- Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ (2000) Microglia, amyloid and dementia in Alzheimer disease. A correlative study. Neurobiol Aging 21(1):39–47. https://doi.org/10.1016/s0197-4580(00)00094-4 - DOI - PubMed
-
- Bales KR, Du Y, Holtzman D, Cordell B, Paul SM (2000) Neuroinflammation and Alzheimer’s disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging 21(3):427–432. https://doi.org/10.1016/s0197-4580(00)00143-3 (discussion 451–423) - DOI - PubMed
-
- Bauer J, Strauss S, Volk B, Berger M (1991) IL-6-mediated events in Alzheimer’s disease pathology. Immunol Today 12(11):422 - DOI
-
- Baum W, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28(1):110–113. https://doi.org/10.1097/jcp.0b013e318160862c - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical